/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | NRXPNRX Pharmaceuticals, |
|---|---|
| Last close | $2.62 |
| Change % | -0.38% |
| Market cap | $113M |
| P/E | — |
| Revenue | $1M |
| Rev growth (YoY) | — |
| Net income | $-28622000 |
| Net margin | -1980.8% |
| EPS (diluted) | $-0.60 |
| Piotroski F-ScoreUNVALIDATED | 4 |
| Altman Z-ScoreUNVALIDATED | -36.67 |
| Beneish M-ScoreUNVALIDATED | — |
| Next earnings | 08-11 → 08-21 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Green = best in the row among the compared names. Educational only — not investment advice.